Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$2.70 -0.9%	$2.36	$1.60 ▼ $17.55	$72.96M	1.87	385,631 shs	98,046 shs
LEXX Lexaria Bioscience	$1.04 +1.5%	$1.30	$0.95 ▼ $4.44	$18.17M	0.9	155,189 shs	45,702 shs
MCRB Seres Therapeutics	$7.09 +0.6%	$9.71	$6.53 ▼ $30.60	$61.91M	2.89	145,888 shs	57,131 shs
TCRX TScan Therapeutics	$1.47 +1.4%	$1.38	$1.02 ▼ $9.29	$83.19M	1.06	404,032 shs	412,603 shs

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	-1.10%	-8.49%	+10.45%	-3.75%	-78.51%
LEXX Lexaria Bioscience	+1.47%	+6.70%	-11.54%	-29.59%	-72.76%
MCRB Seres Therapeutics	+0.57%	-4.70%	-24.57%	-53.31%	-61.54%
TCRX TScan Therapeutics	+1.38%	+2.08%	-7.55%	-30.00%	-82.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANRO Alto Neuroscience	2.2888 of 5 stars	3.3	3.0	0.0	3.1	0.8	0.6
LEXX Lexaria Bioscience	2.7301 of 5 stars	3.5	3.0	0.0	3.3	1.7	0.6
MCRB Seres Therapeutics	2.8742 of 5 stars	2.9	1.0	4.6	2.0	0.8	0.0
TCRX TScan Therapeutics	3.3 of 5 stars	4.5	1.0	0.0	2.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.57	Moderate Buy	$15.40	471.43% Upside
LEXX Lexaria Bioscience	3.00	Buy	$7.00	576.33% Upside
MCRB Seres Therapeutics	1.80	Reduce	$73.67	939.02% Upside
TCRX TScan Therapeutics	3.00	Buy	$7.80	430.61% Upside

Current Analyst Ratings Breakdown

Latest LEXX, TCRX, MCRB, and ANRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	ANRO Alto Neuroscience	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
5/7/2025	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $10.00
5/6/2025	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
4/8/2025	TCRX TScan Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/7/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
3/21/2025	ANRO Alto Neuroscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/20/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/14/2025	MCRB Seres Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$20.00 ➝ $15.00
3/14/2025	TCRX TScan Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$10.00
3/7/2025	TCRX TScan Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$14.00 ➝ $3.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A	N/A
LEXX Lexaria Bioscience	$525.92K	34.56	N/A	N/A	$0.48 per share	2.16
MCRB Seres Therapeutics	$126.33M	0.49	N/A	N/A	($0.35) per share	-20.26
TCRX TScan Therapeutics	$4.42M	18.82	N/A	N/A	$3.15 per share	0.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$36.31M	-$2.34	N/A	N/A	N/A	N/A	-49.28%	-33.52%	8/12/2025 (Estimated)
LEXX Lexaria Bioscience	-$5.80M	-$0.59	N/A	N/A	N/A	-1,473.04%	-88.88%	-83.59%	7/11/2025 (Estimated)
MCRB Seres Therapeutics	-$113.72M	-$4.60	N/A	N/A	N/A	N/A	N/A	-55.08%	8/12/2025 (Estimated)
TCRX TScan Therapeutics	-$89.22M	-$1.09	N/A	N/A	N/A	-1,188.88%	-58.72%	-36.02%	8/11/2025 (Estimated)

Latest LEXX, TCRX, MCRB, and ANRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ANRO Alto Neuroscience	-$0.59	-$0.53	+$0.06	-$0.56	N/A	N/A
5/12/2025	Q1 2025	TCRX TScan Therapeutics	-$0.28	-$0.26	+$0.02	-$0.26	$1.62 million	$2.17 million
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A
4/14/2025	Q2 2025	LEXX Lexaria Bioscience	-$0.16	-$0.15	+$0.01	-$0.15	$0.14 million	$0.17 million
3/20/2025	Q4 2024	ANRO Alto Neuroscience	-$0.65	-$0.56	+$0.09	-$0.56	N/A	N/A
3/5/2025	Q4 2024	TCRX TScan Therapeutics	-$0.27	-$0.29	-$0.02	-$0.30	$1.43 million	$0.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
LEXX Lexaria Bioscience	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.05	13.10	13.09
LEXX Lexaria Bioscience	N/A	29.62	29.62
MCRB Seres Therapeutics	N/A	1.12	1.12
TCRX TScan Therapeutics	0.13	9.56	9.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
LEXX Lexaria Bioscience	13.06%
MCRB Seres Therapeutics	59.34%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	11.13%
LEXX Lexaria Bioscience	26.40%
MCRB Seres Therapeutics	4.70%
TCRX TScan Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	N/A	27.07 million	N/A	N/A
LEXX Lexaria Bioscience	7	17.56 million	12.92 million	Not Optionable
MCRB Seres Therapeutics	330	8.73 million	162.03 million	Optionable
TCRX TScan Therapeutics	100	56.59 million	51.90 million	Not Optionable

LEXX, TCRX, MCRB, and ANRO Headlines

Recent News About These Companies

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 28 at 7:00 AM | globenewswire.com

TScan Therapeutics (NASDAQ:TCRX) & Relay Therapeutics (NASDAQ:RLAY) Head to Head Contrast

May 25, 2025 | americanbankingnews.com

Lynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock

May 22, 2025 | insidertrades.com

Head-To-Head Analysis: TScan Therapeutics (NASDAQ:TCRX) versus Twist Bioscience (NASDAQ:TWST)

May 22, 2025 | americanbankingnews.com

TScan Therapeutics (NASDAQ:TCRX) Announces Quarterly Earnings Results

May 14, 2025 | marketbeat.com

Equities Analysts Set Expectations for TCRX Q2 Earnings

May 13, 2025 | marketbeat.com

Wedbush Equities Analysts Cut Earnings Estimates for TCRX

May 11, 2025 | marketbeat.com

Research Analysts Issue Forecasts for TCRX Q1 Earnings

May 10, 2025 | marketbeat.com

What Analysts Are Saying About TScan Therapeutics Stock

May 10, 2025 | nasdaq.com

HC Wainwright Has Lowered Expectations for TScan Therapeutics (NASDAQ:TCRX) Stock Price

May 9, 2025 | marketbeat.com

TScan Therapeutics' (TCRX) "Outperform" Rating Reiterated at Wedbush

May 8, 2025 | marketbeat.com

3TCRX : What Analysts Are Saying About TScan Therapeutics Stock

May 7, 2025 | benzinga.com

TScan Therapeutics (TCRX) to Release Earnings on Monday

May 7, 2025 | marketbeat.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Buy" from Analysts

May 5, 2025 | marketbeat.com

TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting

April 30, 2025 | nasdaq.com

Adage Capital Partners GP L.L.C. Trims Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)

April 30, 2025 | marketbeat.com

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

April 28, 2025 | globenewswire.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 9.62%

April 17, 2025 | aaii.com

Needham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)

April 9, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX, TCRX, MCRB, and ANRO Company Descriptions

Alto Neuroscience NYSE:ANRO

$2.70 -0.03 (-0.92%)

Closing price 05/29/2025 03:59 PM Eastern

Extended Trading

$2.70 0.00 (0.00%)

As of 05/29/2025 04:04 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Lexaria Bioscience NASDAQ:LEXX

$1.03 +0.02 (+1.47%)

Closing price 05/29/2025 03:58 PM Eastern

Extended Trading

$1.03 0.00 (0.00%)

As of 05/29/2025 07:38 PM Eastern

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Seres Therapeutics NASDAQ:MCRB

$7.09 +0.04 (+0.57%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$7.08 -0.01 (-0.21%)

As of 04:45 AM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

TScan Therapeutics NASDAQ:TCRX

$1.47 +0.02 (+1.38%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$1.46 0.00 (-0.34%)

As of 05/29/2025 06:23 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time